Stocks Health care ADPT
NASDAQ · Health careAdaptive Biotechnologies Corp (ADPT)
Adaptive Biotechnologies Corp brought in $308.1M of revenue over the twelve months to June 30, 2026, up 50.1% from a year earlier. It posted a net loss of $63.9M. In fiscal 2025 capital spending exceeded operating cash flow by $48.9M. At June 30, 2026 it held $169.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 4, 2026.
What Adaptive Biotechnologies Corp does
Adaptive Biotechnologies Corp is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ADPT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $277M | -$59.5M | -$0.39 | -$48.9M |
| 2024 | $179M | -$159.5M | -$1.08 | -$98.9M |
| 2023 | $170.3M | -$225.3M | -$1.56 | -$167M |
| 2022 | $185.3M | -$200.2M | -$1.40 | -$200.3M |
| 2021 | $154.3M | -$207.3M | -$1.48 | -$254.5M |
| 2020 | $98.4M | -$146.2M | -$1.11 | -$168.5M |
Where ADPT ranks in Health care
Latest SEC filings
What Adaptive Biotechnologies Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 4, 2026Quarterly report 10-Q · period to June 30, 2026
- July 29, 2026
- June 22, 2026
- June 15, 2026Other event 8-K
- June 9, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 5, 2026Quarterly report 10-Q · period to March 31, 2026
- May 5, 2026
- April 24, 2026
- April 24, 2026Additional proxy material DEFA14A
Insider trades
What the people running Adaptive Biotechnologies Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $3.5M worth of shares in the last 90 days and bought none on the open market. Most of the selling (93%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 16, 2026 | Lo FrancisChief People Officer | Exercised options | 53,091 | $644.5K |
| September 16, 2026 | Lo FrancisChief People Officer | Exercised options | 13,398 | $113.3K |
| September 16, 2026 | Lo FrancisChief People Officer | Exercised options | 15,629 | $62.4K |
| September 16, 2026 | Lo FrancisChief People Officer | Exercised options | 23,442 | $190.3K |
| September 16, 2026 | Lo FrancisChief People Officer | Soldpre-planned (10b5-1) | 107,537 | $3M |
| September 16, 2026 | Lo FrancisChief People Officer | Soldpre-planned (10b5-1) | 7,869 | $224.8K |
| September 15, 2026 | Bobulsky SusanChief Commercial Officer, MRD | Soldpre-planned (10b5-1) | 1,195 | $32.3K |
| August 31, 2026 | Owen Katey EinterzDirector | Gave as a gift | 12,539 | - |
| August 26, 2026 | Owen Katey EinterzDirector | Sold | 9,615 | $250K |
Questions about ADPT
What does Adaptive Biotechnologies Corp do?
Adaptive Biotechnologies Corp is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ADPT.
Is Adaptive Biotechnologies Corp profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $63.9M on revenue of $308.1M.
How much revenue does Adaptive Biotechnologies Corp make?
Over the twelve months to June 30, 2026 Adaptive Biotechnologies Corp reported revenue of $308.1M. That is 50.1% more than a year earlier.
When did Adaptive Biotechnologies Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 4, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 18, 2026.
Similar companies
Compare ADPT with
Follow ADPT
Get an email when Adaptive Biotechnologies Corp files with the SEC: results, executive changes, material agreements and annual reports.
Follow ADPT: get an email when it filesWhere the numbers come from
Financial figures are the values Adaptive Biotechnologies Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.